Objective This prospective pilot study was conducted to compare the usefulness of measuring fecal lactoferrin (LI) to that of fecal occult blood (FOB) test for detection of colorectal diseases. Patients and Methods The subjects were 351 patients whounderwentcolonoscopy. Afecal sample was obtained on the day before colonoscopy. Fecal Lf was measured by enzyme-linked immunosorbent assay. The FOBtest was performed by combined assay (latex agglutination) of hemoglobinand transferrin. Results The specificities of the fecal Lf and FOBtests were the same (88.7 %). For patients with colorectal cancer (13), colorectal polyp (69), ulcerative colitis (18), Crohn' s disease (13), non-specific colitis (8), internal hemorrhoids (60), colon diverticulum (27), and miscellaneous diseases of the colon (10), the rates of positivity for fecal Lf were II 13, 14/69, 12/18, 7/13, 4/8, 22/60, 8/27, and 6/10, respectively. The corresponding rates for FOB were 8/13, 12/69, ll/18, 4/13, 4/8, 9/60, 2/27, and 1/10. For patients with internal hemorrhoids, the rate of positivity for fecal Lf was significantly higher than that for FOB. In other disease groups, there was no significant difference in the rate of positivity between fecal Lf and FOB. Conclusion These findings suggest that measurement of fecal Lf is as useful as FOBin detecting colorectal diseases. (Internal Medicine 39: 778-782, 2000) 
Introduction
To screen for colorectal diseases, immunological fecal occult blood tests using fecal hemoglobin (Hb) as a marker are widely performed (1) (2) (3) (4) . However, Hb is unstable in feces, leading to false-negative results, and this test is of no use for the detection of lesions without bleeding. Therefore, development of another markerthat is stable in feces and has excellent sensitivity is required. Wehave already reported that lactoferrin (Lf), which is released from specific granules in neutrophils, is stable in feces and is a good marker of the activity of inflammatory bowel diseases (ulcerative colitis, Crohn' s disease) (5, 6) . Wehave also reported that the fecal Lf level is high in patients with colorectal neoplasm as well as in those with inflammatory bowel diseases (6) . Weconducted a prospective pilot study to comparethe usefulness of measuring the fecal Lf level and fecal occult blood tests, using fecal samples obtained on the day before colonoscopy.
Patients and Methods
Patients and fecal sampling The subjects included 35 1 patients who underwent colonoscopy at Osaka Medical College Hospital (Second Department of Internal Medicine) and gave written informed consent in accordance with the Helsinki Declaration. Patients with severe liver, gallbladder, or pancreatic disease were excluded from the study. Patients obtained fecal samples the day before colonoscopy and brought the samples on the day of colonoscopy. Briefly, a grooved stick was used to pick up samples from several parts of feces up to a fixed total amount (30-80 mg), then the stick was put into the case containing 2 ml of a buffer solution containing antibiotics. Colonoscopies were performed by 8 experienced, board-certified endoscopists. The entire colon was observed, and biopsy for diagnosis was per- Measurement of fecal Lf and fecal occult blood The level of fecal Lf was measured using an SD-8852 enzyme-linked immunosorbent assay (ELISA) kit for fecal Lf (Shionogi & Co. Ltd., Osaka) (7). The principle of this kit is sandwich ELISA using rabbit anti-human Lf antibody (Dakopatts, Glostrup, Denmark), visualized by tetramethylbendizine. As an authentic protein, purified human Lf (Cappel Co., Durham, NC) was used. Fecal occult blood test was performed using LA hemochaser® (Shionogi & Co. Ltd.) (8) . All sample assays were performed without knowledge of patient diagnosis.
Stability of fecal Lf and fecal occult blood Stool samples (n=20) were stored without treatment (not in buffer solution) or in buffer solution for 1, 3, 7 days at room temperature before freezing and subsequent analysis. LA hemochaser is based on qualitative analysis. For quantitative analysis of fecal occult blood, therefore, fecal hemoglobin was measured by ELISA as described in our previous study (9) .
Statistical analysis For statistical analysis, McNemar's test was used. P values less than 0.05 were considered statistically significant. Sensitivity was defined as the rate of positivity in each disease group, and specificity as the proportion of true negatives to the sum of true negatives and false-positives.
Results

Stability of fecal Lf and fecal Hb
The data are shownin Fig. 1 . The concentration of Lf and Hbwas expressed as a percentage of the original concentration at 0 hour. Whenstool samples were left without buffer solution, fecal Hblost their antigenicity rapidly. In buffer solution, however, both fecal Lf and Hb remained stable for 3 days (more than 75%).
Definitive diagnosis Abnormal findings were observed on colonoscopy in 218 of 351 cases. Definitive diagnosis by colonoscopy was colorectal cancer: 13 cases, colorectal polyp: 69 cases, ulcerative colitis: 18 cases, Crohn's disease: 13 cases, non-specific colitis: 8 cases, internal hemorrhoids: 60 cases, colonic diverticulum: 27 cases, other lesions including elevated lesion of the colon without further information: 4 cases, old tuberculosis of the colon: 2 cases, periappendicular abscess: 1 case, mucosal prolapse syndrome: 1 case, an intrarectal foreign body: 1 case, and post-polypectomy state: 1 case. There were no abnormal findings observed by colonoscopy in 1 33 cases. A polyp was defined as an adenoma5 mmor more in diameter. Patients with both polyp and internal hemorrhoids, and patients with both polyp and diverticulum, were classified into the polyp group. Patients with internal hemorrhoids and diverticulum were classified into the internal hemorrhoids group.
Determination of the cut-off value for fecal Lf level Based on receiver operating characteristic (ROC) analysis (10) using the fecal Lf levels for all 351 subjects, the optimal cut-off value for fecal Lf level could not be determined ( Fig.   1 ). As a cut-off value for fecal Lflevel, weused 65 ng/ml, with which the specificity was the same as that for the fecal occult blood test.
The sensitivity and specificity in subjects with no abnormality, subjects with abnormality, and the group of all subjects Among133 subjects with no abnormality on colonoscopy, fecal Lf was positive in 15 with a specificity of 88.7%, and the fecal occult blood test was positive in 15 with a specificity of 88.7% (Table 1 ). The specificities of the fecal Lf test and fecal occult blood test were the same. Amongthe 218 subjects with abnormality on colonoscopy (subjects whowere excluded from the group without abnormality), fecal Lf was positive in 80 cases with a sensitivity of 36.7%, and the fecal occult blood test was positive in 5 1 with a sensitivity of 23.4%. In this group, the sensitivity of the fecal Lf test was significantly higher than that of the fecal occult blood test.
The sensitivity in each coiorectai disease group The sensitivities of the fecal Lf test and fecal occult blood test were compared in the patient groups for each coiorectai disease (Table 2 ). In the group with internal hemorrhoids, fecal Lf was positive in 22 of 60 cases with a sensitivity of 36.7%, and the fecal occult blood test was positive in 9 of 60 cases showing a sensitivity of 15.0%. In this group, the sensitivity of the fecal Lf test was significantly higher than that of the fecal occult blood test. In the groups with Crohn's disease, colonic diverticulum, and other diseases, the sensitivity of the fecal Lf test was higher than that of the fecal occult blood test, but not to a statistically significant extent. Among8 cases of active Crohn' s disease, fecal Lf test was positive in 6 with a sensitivity of 75% and the fecal occult blood test was positive in 1 with a sensitivity of 12.5%. Crohn's disease was defined as being in the active stage whenthe score of Crohn's disease activity index (CDAI) (ll) was more than 150 and/or active inflammation was observed by colonoscopy. In the groups with cancer, polyp, and ulcerative colitis, there wasno significant difference between the sensitivity of the fecal Lf test and that of the fecal occult blood test. Whenpatients with ulcerative colitis were divided into an active stage group and inactive stage group, there was no significant difference between the sensitivity of the fecal Lf test and that of the fecal occult blood test in the two groups. Among8 cases of cancer with positive fecal occult blood test, 2 were right-sided and 6 were left-sided.
Among7 cases of cancer with positive fecal Lf test, 2 were right-sided and 5 were left-sided. Among12 cases of polyp with positive fecal occult blood test, 6 were right-sided and 6 were left-sided. Among14 cases of polyp with positive fecal Lf test, 7 were right-sided and 7 were left-sided. Among13 cases of colon cancer (Dukes A in 6, Dukes B in 4, Dukes C in 3), 4 cases had negative fecal Lf and fecal occult blood tests. All of the 4 cases had Dukes A cancer. Forty-six of 69 cases (66.7%) of colon polyp had negative fecal Lf and fecal occult However, Hb tends to suffer degradation by fecal bacteria and digestive enzymes, leading to loss of antigenicity. In our previous study, we showed that combinedmeasurementof Hb and Tf had a higher sensitivity for colonic neoplasms than a single measurement of Hb (16, 17) . The LA hemochaser, which we used for fecal occult blood testing in the present study, is based on latex agglutination detection of Hb and Tf, and has already been widely used in screening for colorectal cancer. As shown in Fig. 2 , both fecal Lf and Hb were stable in buffer solution for 3 days. Since stool samples were stored in buffer solution in the present study, there should be no difference in the stability of fecal Lf and Hb after defecation. In the intestine, however, Lf seems to be more stable than Hb. Therefore, we investigated the location (right-sided colon or left-sided colon) of the cancer or polyp that was associated with either positive fecal Lf test or positive fecal occult blood test. The results showed no difference in the site distribution between the Lf positive-lesion and fecal occult blood positive-lesion. In the present prospective study, we obtained a fecal sample on the day before colonoscopy and established definitive diagnoses of colorectal disease using colonoscopy. The determination of the cut-off value for fecal Lf level was described in the Results. The criteria for positive fecal occult blood test were according to the instructions for use of the kit. The rate of positivity for both the fecal Lf test and fecal occult blood test for subjects with no abnormality on colonoscopy was 1 1.3%, which was higher than that normally observed in screening. This is because the subjects of this study were patients whohad consulted a hospital. This finding is also reasonable given the reasons why these subjects underwent colonoscopy. If the subjects included many patients who had already had a positive fecal occult blood test in another hospital, the numberof falsepositives due to physiological bleeding would be increased, and the rate of positivity amongsubjects with no abnormality would rise. Our subjects also included patients with symptoms of macroscopic bleeding, suggesting that our subjects tended to have a subtype of each disease that tended to feature bleeding. Although fecal occult blood testing was expected to be advantageous in the present study using these subjects, the fecal Lf test exhibited a significantly higher sensitivity than the fecal occult blood test for subjects with abnormality. In the groups with cancer, polyp, ulcerative colitis, and non-specific colitis, the sensitivities of the fecal Lf test and fecal occult blood test were almost the same. In the groups with Crohn's disease, colonic diverticulum, and other diseases, the sensitivity of the fecal Lf was slightly higher than that of the fecal occult blood test, but the difference was not statistically significant. For patients with internal hemorrhoids, the sensitivity of the fecal Lf test was significantly higher than that of the fecal occult blood test. The Valsalva maneuver is useful as a method for detecting mild hemorrhoids. All hemorrhoids in our subjects were apparent even without using the Valsalva maneuver. In the present study, it was not investigated whether hemorrhoids prolapsed out of the anus. Therefore, the grade of hemorrhoids showing positive fecal Lf test was unknown. Local inflammation accompanied by internal hemorrhoids may be sensitively reflected by fecal Lf level. These findings show that the measurement of fecal Lf level has someadvantageous aspects in detecting colorectal diseases. However, for the detection of colorectal neoplasms such as cancers and polyps, the usefulness of the two tests was almost the same. It cannot be concluded that the fecal occult blood test should be replaced by fecal Lf test as a method of screening for colorectal cancer. Interestingly, the numbers of cases showing positive fecal occult blood test but negative fecal Lf test and vice versa were 65 of218 (28.8%) and 23 of82 (28.1%) for subjects with abnormality and those with neoplasm, respectively. As for possible mechanisms of dissociated results with fecal Lf and fecal occult blood tests in patients with neoplasm, the following aspects should be considered; whether the lesion bleeds easily, the infiltration of neutrophils in the lesion, the amount of Lf contained in the lesion, and the location of the lesion. These high rates of dissociation between the two methods mean that the fecal occult blood test and fecal Lf test may compensate each other in the detection of colorectal diseases. In conclusion, the present findings suggest that measurement of fecal Lf is as useful as that of fecal occult blood for detecting various colorectal diseases. Andthe results of this pilot study indicate that it is worthy to continue the prospective study using this protocol to confirm whether fecal Lf test is superior to fecal occult blood test. In order to verify that the fecal Lf test is advantageous as a screening test for colorectal diseases, further studies will be needed to clarify the origin of the Lf detected in feces and the characteristics of patients positive for fecal Lf.
